Cherry Creek Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Cherry Creek Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$223K	Sell	53,972 -11,026	-17%	-$37.4K	0.09%	116
2026 Q2	$239K	Sell	64,998 -5,538	-8%	-$18.4K	0.09%	113
2026 Q1	$217K	Buy	70,536 +3,859	+6%	+$14.9K	0.09%	111
2025 Q4	$273K	Sell	66,677 -104	-0.2%	-$515	0.12%	90
2025 Q3	$326K	Buy	66,781 +2,649	+4%	+$13.9K	0.14%	87
2025 Q2	$325K	Buy	64,132 +535	+0.8%	+$2.63K	0.15%	85
2025 Q1	$336K	Buy	63,597 +1,470	+2%	+$10.7K	0.18%	82
2024 Q4	$420K	Buy	62,127 +4,787	+8%	+$32.2K	0.21%	67
2024 Q3	$378K	Sell	57,340 -35,998	-39%	-$258K	0.2%	70
2024 Q2	$700K	Buy	93,338 +35,782	+62%	+$312K	0.37%	45
2024 Q1	$574K	Buy	57,556 +39,703	+222%	+$442K	0.31%	52
2023 Q4	$176K	Buy	+17,853	New	+$127K	0.11%	96

Other funds holding RXRX

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.14B AUM 18.43% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TWM

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Cherry Creek Investment Advisors's RXRX Position: Q3 2026 in Review

Cherry Creek Investment Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 17% in Q3 2026, selling an estimated $37.4K and leaving 53,972 shares worth $223K. The position accounts for 0.09% of the portfolio, ranked #116.

Cherry Creek Investment Advisors first reported a position in RXRX in Q4 2023 and has held it in 12 quarters since. The position peaked at $700K in Q2 2024. 27 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Cherry Creek Investment Advisors held 53,972 shares of Recursion Pharmaceuticals worth $223K as of Q3 2026.
Cherry Creek Investment Advisors sold 11,026 Recursion Pharmaceuticals shares in Q3 2026, an estimated $37.4K.
Recursion Pharmaceuticals made up 0.09% of Cherry Creek Investment Advisors's portfolio in Q3 2026, its #116 holding.
Cherry Creek Investment Advisors first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
Cherry Creek Investment Advisors's Recursion Pharmaceuticals position peaked at $700K in Q2 2024.
27 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Cherry Creek Investment Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.